肝内胆管细胞癌(Intrahepatic cholangiocarcinoma, ICC)是一种恶性程度很高的肝脏肿瘤,近年来其发病率和死亡率不断上升。然而,由于缺乏具有代表性的遗传标记以及现有的基因组学研究仍较为有限,ICC的靶向治疗面临较大挑战。随着第二代基因测序技术(Next-generation sequencing, NGS)等先进技术的应用,研究者对ICC中遗传异质性的理解得到了极大的拓展,并已发现多个潜在的基因改变。本综述主要讨论ICC基因改变的最新分子研究进展,梳理和讨论NGS技术在ICC临床研究中的应用,特别是针对单个基因的遗传及表观遗传学改变的研究。特别地,我们探讨了新靶向药物对具有特征性遗传标记的ICC患者的潜在疗效。尽管如此,关于ICC术后复发相关的分子生物标志物仍不明确,仍需进一步深入研究。未来,借助NGS技术深入研究ICC的分子分型以及术后复发相关分子标志物,将有助于为ICC患者提供更加精准的个体化治疗方案。Intrahepatic cholangiocarcinoma (ICC) is a highly malignant liver tumor, with increasing incidence and mortality in recent years. However, due to the lack of representative genetic markers and the limited genomic studies available, effective targeted therapy for ICC remains challenging. With the advent of advanced technologies such as next-generation sequencing (NGS), our understanding of the genetic heterogeneity of ICC has greatly expanded, and several potential genetic alterations have been identified. This review discusses the latest molecular research advancements on genetic alterations in ICC, and provides an overview of clinical findings from NGS technology applied to ICC. It specifically focuses on the genetic and epigenetic changes of individual genes and evaluates the efficacy of new targeted therapies in ICC patients, particularly those with characteristic genetic markers. However, molecular biomarkers related to postoperative recurrence in ICC remain unclear and warrant furth
目的:研究肿瘤相关巨噬细胞(TAMs)对人胃癌SGC-7901细胞系生物学功能的影响。方法 :采用佛波酯(PMA)、白细胞介素IL-4和IL-13体外诱导人M2型巨噬细胞,细胞免疫荧光鉴定TAMs。Transwell非接触式共培TAMs和胃癌SGC-7901细胞,侵袭实验、迁移实验检测肿瘤相关巨噬细胞(TAMs)对胃癌SGC-7901细胞侵袭和迁移的影响,酶联免疫吸附法(ELISA)检测实验组和空白对照组胃癌SGC-7901细胞上清中分泌型Sema4D的变化。结果:细胞免疫荧光鉴定M2型巨噬细胞诱导成功;在Transwell共培养体系中,TAMs共培养的胃癌SGC-7901细胞形态学发生改变;Transwell侵袭实验、迁移实验表明,细胞侵袭转移力增强(P<0.01)。与TAMs共培养的胃癌SGC-7901细胞的上清液分泌型Sema4D蛋白明显增多,较空白对照组差异有统计学意义(1224.13±29.43比637.15±33.84,P<0.01)。结论 :TAMs可促进胃癌细胞的浸润转移,其原因可能与分泌型Se m a4D蛋白的表达上调有关。
